Actively Recruiting

Age: 0Years - 100Years
All Genders
NCT06785818

Long-term Follow up Local Registry Study of Kymriah in South Korea

Led by Novartis Pharmaceuticals · Updated on 2026-05-05

500

Participants Needed

16

Research Sites

772 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.

CONDITIONS

Official Title

Long-term Follow up Local Registry Study of Kymriah in South Korea

Who Can Participate

Age: 0Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients who receive tisagenlecleucel infusion in the commercial setting, treated under a managed access program or other pathway, e.g., when product was manufactured for the commercial setting but turned out to be out of specification (OOS).
  • Consented to data collection.
Not Eligible

You will not qualify if you...

  • Patients who are enrolled or will be enrolled in the Novartis long term follow-up protocol CCTL019A2205B.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 16 locations

1

Novartis Investigative Site

Bundang Gu, Gyeonggi-do, South Korea, 13620

Actively Recruiting

2

Novartis Investigative Site

Seongnam-si, Gyeonggi-do, South Korea, 463-712

Actively Recruiting

3

Novartis Investigative Site

Gyeonggi-do, Korea, South Korea, 10408

Actively Recruiting

4

Novartis Investigative Site

Incheon, Korea, South Korea, 405 760

Actively Recruiting

5

Novartis Investigative Site

Seoul, Korea, South Korea, 02841

Actively Recruiting

6

Novartis Investigative Site

Seoul, Korea, South Korea, 08308

Actively Recruiting

7

Novartis Investigative Site

Seoul, Seoul, South Korea, 03080

Actively Recruiting

8

Novartis Investigative Site

Seoul, Seoul, South Korea, 06351

Actively Recruiting

9

Novartis Investigative Site

Seoul, Seoul, South Korea, 150-713

Actively Recruiting

10

Novartis Investigative Site

Busan, South Korea, 49201

Actively Recruiting

11

Novartis Investigative Site

Jeollanam, South Korea, 519763

Actively Recruiting

12

Novartis Investigative Site

Seoul, South Korea, 03722

Actively Recruiting

13

Novartis Investigative Site

Seoul, South Korea, 04401

Actively Recruiting

14

Novartis Investigative Site

Seoul, South Korea, 05505

Actively Recruiting

15

Novartis Investigative Site

Seoul, South Korea, 06591

Actively Recruiting

16

Novartis Investigative Site

Ulsan, South Korea, 44033

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here